180 related articles for article (PubMed ID: 30131069)
21. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.
Nymoen DA; Slipicevic A; Holth A; Emilsen E; Hetland Falkenthal TE; Tropé CG; Reich R; Flørenes VA; Davidson B
Hum Pathol; 2016 Aug; 54():74-81. PubMed ID: 27063471
[TBL] [Abstract][Full Text] [Related]
22. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
23. [Serous and non-serous ovarian carcinoma: histological tumor type as related to the grade of differentiation and disease prognosis].
Ferreira PA; Sallum LF; Sarian LO; Andrade LA; Derchain S
Rev Bras Ginecol Obstet; 2012 May; 34(5):196-202. PubMed ID: 22584853
[TBL] [Abstract][Full Text] [Related]
24. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
25. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.
Zheng W; Fadare O
Int J Clin Exp Pathol; 2012; 5(3):182-6. PubMed ID: 22558471
[No Abstract] [Full Text] [Related]
26. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; Holth A; Dong HP
Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
[TBL] [Abstract][Full Text] [Related]
27. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
28. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Morrison JC; Blanco LZ; Vang R; Ronnett BM
Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
[TBL] [Abstract][Full Text] [Related]
29. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
Okoye E; Euscher ED; Malpica A
Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
[TBL] [Abstract][Full Text] [Related]
30. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
[TBL] [Abstract][Full Text] [Related]
31. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
32. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ
Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
34. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
35. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
36. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Pietzner K; Dietel M; Sehouli J; Darb-Esfahani S
Virchows Arch; 2015 Mar; 466(3):333-42. PubMed ID: 25522951
[TBL] [Abstract][Full Text] [Related]
38. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
39. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.
Maniar KP; Wang Y; Visvanathan K; Shih IeM; Kurman RJ
Am J Surg Pathol; 2014 Jun; 38(6):743-55. PubMed ID: 24441661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]